Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.

Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.

OBJECTIVES:The aim of this study was to evaluate the frequency of transaminase elevations (TE) and total bilirubin elevations (TBE) during the first year of therapy with a single tablet regimen including RPV/FTC/TDF (EPA) in HIV/hepatitis C virus (HCV)-coinfected subjects in clinical practice. METHO...

Full description

Bibliographic Details
Main Authors: Karin Neukam, Nuria Espinosa, Antonio Collado, Marcial Delgado-Fernández, Patricia Jiménez-Aguilar, Antonio Rivero-Juárez, Victor Hontañón-Antoñana, Ana Gómez-Berrocal, Josefa Ruiz-Morales, Dolores Merino, Ana Carrero, Francisco Téllez, María José Ríos, José Hernández-Quero, María de Lagarde-Sebastián, Inés Pérez-Camacho, Francisco Vera-Méndez, Juan Macías, Juan A Pineda, hEPAtic Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4873169?pdf=render

Internet

http://europepmc.org/articles/PMC4873169?pdf=render

Similar Items